Dr Reddy's Lab shares hit one-year low; down nearly 5%

Image
Press Trust of India New Delhi
Last Updated : Mar 09 2017 | 1:22 PM IST
Shares of Dr Reddy's Laboratories today fell by nearly 5 per cent after the company received 13 observations from the US health regulator for its formulation manufacturing facility at Duwada, Visakhapatnam.
The stock went down by 4.6 per cent to Rs 2,720 -- its 52-week low level -- on BSE.
On NSE, it slipped 4.64 per cent to hit its one-year low of Rs 2,714.50.
The stock was the worst performer among the bluechips on both the Sensex and Nifty
"The audit of company's formulation manufacturing facility at Duwada, Visakhapatnam, by the USFDA, has been completed on March 8, 2017. The company has been issued Form 483 with 13 observations, which the company is addressing," Dr Reddy's Laboratories said in a BSE filing.
The firm, however, did not specify the observations.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 09 2017 | 1:22 PM IST

Next Story